Factor XIII – an under diagnosed deficiency – are we using the right assays?

Background:  The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening te...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2010-11, Vol.8 (11), p.2478-2482
Main Authors: LAWRIE, A. S., GREEN, L., MACKIE, I. J., LIESNER, R., MACHIN, S. J., PEYVANDI, F.
Format: Article
Language:English
Subjects:
acquired FXIII deficiency
Adult
Automation
Chemistry, Clinical - methods
Child
Cohort Studies
factor XIII
Factor XIII - analysis
factor XIII deficiency
Factor XIII Deficiency - blood
Factor XIII Deficiency - diagnosis
FXIII assay
Heterozygote
Humans
Immune System
Intensive Care Units
Nephelometry and Turbidimetry - methods
Prevalence
Reproducibility of Results
Wound Healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:  The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2010.04028.x